AVZO-103 Clinical Trial
Phase 1/2
355
about 5 years
18+
9 sites in FL, MA, NC +4
What this study is about
Researchers are testing AVZO-103, a new drug, to see if it's safe and effective in people with urothelial cancer or other solid tumors. The trial will also look at how the body processes the drug and whether it can kill cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AVZO-103
- 2.Take Combination Agent
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1), Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1), Objective Response Rate (ORR) (Phase 2)
Secondary: Disease Control Rate (DCR) (Phase 1 and 2), Duration of Response (DOR) (Phase 1 and 2), Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 2), Objective Response Rate (ORR) (Phase 1), Overall Survival (OS) (Phase 1 and 2), PK Parameters: Accumulation ratio (AR) (Phase 1), PK Parameters: Apparent Clearance (CL/F) (Phase 1), PK Parameters: Apparent volume of distribution at steady-state (Vss) (Phase 1)
Oncology